Across Canada, some jurisdictions have already approved or are working towards expanding the scope of certified pharmacists to include the administration of Sublocade.
Adding to the challenge is the current lack of widespread screening programs for early stage T1DM in the general population, making it difficult to identify all patients who may benefit from teplizumab.
It’s the third generic semaglutide product approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.
